02/10/2026
Schedule 3 Cannabis What We Know So Far (Q1 2026 Update)
As of early 2026, cannabis remains in a regulatory transition. Reclassification to Schedule 3 would acknowledge accepted medical use and lower abuse potential compared to Schedule 1 but it does not equal full legalization.
Here’s what’s clear so far:
• Schedule 3 would allow expanded medical research
• FDA oversight would still apply to drug development
• State medical and adult-use programs would continue separately
• Hemp-derived cannabinoids remain federally legal under current law
• Businesses still face compliance, banking, and regulatory hurdles
This shift matters because research we all deserve clean effective inexpensive medication. The future is natural!
We break down what this actually means, what hasn’t changed, and why the details matter here:
👉 https://releafcbd.com/blogs/releaf-news-education/schedule-3-cannabis-research
Schedule 3 is opening the door to real cannabinoid research. Learn how CBD, CBG, CBC and CBN are shaping the future of natural medicine.
